Open AccessNicotinic acid/laropiprant: a new lipid‐modifying therapy
Author(s) -
Chaplin Steve,
Evans Marc
Publication year - 2009
Publication title -
future prescriber
Language(s) - English
Resource type - Journals
eISSN - 1931-2261
pISSN - 1468-9871
DOI - 10.1002/fps.44
Subject(s) - nicotinic agonist , medicine , pharmacology , niacin , receptor
Cardiovascular disease (CVD) is a leading cause of death in the UK. 1 Blood choleserol levels are a key risk factor for CVD, and can be modified by both drug treatment and lifestyle changes. In this article, Steve Chaplin considers the available clinical data on a new lipid‐modifying therapy, a modified‐release formulation of nicotinic acid and laropiprant; and Marc Evans comments on its potential contribution to reducing the risk of CVD. Copyright © 2009 John Wiley & Sons, Ltd.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom